Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Investing Activities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Cash from Investing Activities for 16 consecutive years, with -$6.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 68.15% year-over-year to -$6.5 million, compared with a TTM value of -$46.4 million through Dec 2025, down 8191.43%, and an annual FY2025 reading of -$46.4 million, down 8191.43% over the prior year.
  • Cash from Investing Activities was -$6.5 million for Q4 2025 at Amicus Therapeutics, down from -$1.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $86.6 million in Q1 2021 and bottomed at -$68.1 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is $11.1 million, with a median of $16.6 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities skyrocketed 122.44% in 2021, then tumbled 536.0% in 2025.
  • Year by year, Cash from Investing Activities stood at -$68.1 million in 2021, then rose by 2.03% to -$66.7 million in 2022, then surged by 64.08% to -$24.0 million in 2023, then grew by 14.88% to -$20.4 million in 2024, then skyrocketed by 68.15% to -$6.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for FOLD at -$6.5 million in Q4 2025, -$1.3 million in Q3 2025, and -$5.8 million in Q2 2025.